[go: up one dir, main page]

Ziedins et al., 2004 - Google Patents

Factor VIIa replacement therapy in factor VII deficiency

Ziedins et al., 2004

View HTML @Full View
Document ID
754386358075182193
Author
Ziedins K
Rivard G
Pouliot R
Butenas S
Gissel M
Parhami‐Seren B
Mann K
Publication year
Publication venue
Journal of Thrombosis and Haemostasis

External Links

Snippet

Factor (F) VII deficiency is an autosomal recessive disorder for which a replacement therapy is not universally available; recombinant FVIIa has been utilized as a therapeutic substitute. As FVII competes with FVIIa for binding to tissue factor in initiating the extrinsic pathway of …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Ziedins et al. Factor VIIa replacement therapy in factor VII deficiency
Lawson et al. Challenges for providing effective hemostasis in surgery and trauma
Ten Cate et al. Coagulation factor and protease pathways in thrombosis and cardiovascular disease
Kalafatis et al. The regulation of clotting factors
Duckers et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
Butenas et al. Mechanism of factor VIIa–dependent coagulation in hemophilia blood: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.
Spronk et al. The blood coagulation system as a molecular machine
Rapaport et al. The tissue factor pathway: how it has become a “prima ballerina”
Butenas et al. “Normal” thrombin generation: Presented in part at the XVIth congress of the international society on thrombosis and haemostasis, june 6-12, 1997, Florence, Italy (abstr PS-1653), at the 15th international congress on thrombosis, october 16-21, 1998, Antalya, Turkey (abstr 234), and at the 40th annual meeting of the American society of hematology, december 4-8, 1998, Miami Beach, FL (abstr 151).
Ieko et al. β2‐glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
US20070212743A1 (en) Assays for Determining Anticoagulant Cofactor Activity
US20090298103A1 (en) Predicting hemostatic risk; dependence on plasma composition
Whelihan et al. Coagulation procofactor activation by factor XIa
Goodnight et al. Hereditary thrombophilia
Mehic et al. Natural anticoagulants: a missing link in mild to moderate bleeding tendencies
Butenas et al. The function of factor XI in tissue factor-initiated thrombin generation
BR112014004297B1 (en) USE OF AN ANTITHROMBIN III INHIBITOR IN THE TREATMENT OR PREVENTION OF BLEEDING
Abildgaard Antithrombin–early prophecies and present challenges
Santoro et al. Factor XI deficiency: a description of 34 cases and literature review
Asakura et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases
van Geffen et al. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients
Brodin et al. Regulation of thrombin generation by TFPI in plasma without and with heparin
Tabatabaei et al. Congenital factor XI deficiency
Astermark et al. Anti-and procoagulant activities in factor VII-deficient subjects
Amiral et al. The various assays for measuring activity states of factor VIIa in plasma and therapeutic products: Diagnostic value and analytical usefulness in various pathophysiological states